507 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
represent changes in fair value of contingent consideration related to CyDex and Metabasis transactions.
(4) Excess tax benefits from share-based
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Entry into a Material Definitive Agreement
7:36am
potential of BOT/BAL program in delivering benefits to patients across the solid tumor landscape, Ligand may not receive expected revenue under
8-K
EX-99.1
qtvj5onoyegq
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
8-K/A
EX-99.1
21dqbesy2
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
bkvqglc4num
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
syroauaj8lwjhg7mtb
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
cfwiy s543s
18 Sep 23
Other Events
5:26pm
8-K
EX-99.1
m6fp7
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
dtklc
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
hnp0t
5 Dec 22
Departure of Directors or Certain Officers
7:03am